Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-αvβ6-BP PET/CT in Post-COVID-19 Patients
NCT04376593Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- May 2020
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-αvβ6-BP in coronavirus disease 2019 (COVID-19), sponsored by University of California, Davis. Primary endpoint: Administration of 18F-αvβ6-BP at 6 months. Started May 2020; status: completed.
02
Drugs
18F-αvβ6-BP
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04376593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376593.